Losartan and Social Processing
ConditionSocial Cognition
Trial statusRecruiting
Trial phaseEarly Phase 1
Trial typeInterventional
Biological sexAll
Age18-50
SponsorUniversity of Oxford
About this trial
This study explores the effects of single-dose losartan (50mg) versus placebo on social processing in healthy volunteers.
Eligibility criteria
Qualifiers
Willing and able to provide informed consent
Aged 18-50 years
Sufficient written and spoken English skills to understand what the study involves, and to complete the questionnaires
Non- or light-smoker (5 cigarettes a day, if vaping: less than 50 puffs)
Disqualifiers
Current DSM-5 axis-I diagnosis (based on SCID results at screening) or history of a severe psychological disorder such as psychotic disorder, bipolar disorder, alcohol or substance abuse, or post-traumatic stress disorder
First-degree family member with severe psychiatric illness (including psychosis, bipolar disorder, unipolar psychotic depression).
CNS-medication last 6 weeks (including as part of another study)
Current blood pressure or other heart medication, including aliskiren and beta blockers)
Trial design
Treatments tested in this trial
- Losartan potassium 50mg
- Placebo
Treatment groups
68 Participants
are divided into 2 treatment groupsSponsors and collaborators
University of Oxford
Lead sponsor
National Institute for Health Research, United Kingdom
Collaborator
Source ClinicalTrials.gov